Acute Respiratory Distress Syndrome



FIGURE 28.1 Cross-sectional view of alveoli in acute respiratory distress syndrome. *AC,* Alveolar consolidation; *AT,* atelectasis; *HM,* hyaline membrane; *M,* macrophage.

DALHOUSIE UNIVERSITY

References

- Desjardins & Burton (2020), Ch. 28
- Fan, E., Brodie, D., & Slutsky, A. S. (2018). Acute respiratory distress syndrome advances in diagnosis and treatment. *JAMA - Journal of the American Medical Association*, *319*(7), 698–710. https://doi.org/10.1001/jama.2017.21907
- Ranieri, V. M., Rubenfeld, G. D., Thompson, B. T., Ferguson, N. D., Caldwell, E., Fan, E., … Slutsky, A. S. (2012). Acute respiratory distress syndrome: The Berlin definition. *JAMA - Journal of the American Medical Association*, *307*(23), 2526–2533. https://doi.org/10.1001/jama.2012.5669



ARDS Video

ARDS Pathophysiology Animation

Definition

- First described in 1967 by Ashbaugh et al
- In 1994, American-European Consensus Conference (AECC) re-defined the definition of ARDS as:
  - Acute onset of hypoxemia
  - PaO2/FiO2 < 200 mmHg
  - Bilateral infiltrates on CXR
  - No evidence of L Atrial Hypertension
- **Acute Lung Injury (ALI)**
  - Considered to be same as ARDS but with ***less severe hypoxemia***
  - **Pa02/Fi02 < 300**

What was lacking in this definition?

ARDS – Berlin definition (2012)

1. What is the definition of ARDS and how are the levels of severity determined?

- **Term "ALI" not to be used anymore**
  - PaO2/FiO2 200-300 would now have "mild ARDS."
- **Onset** of ARDS must be **acute**, defined as within 7 days of some defined event, which may be sepsis, pneumonia, or worsening respiratory symptoms.
  - Most cases of ARDS occur within 72 hours of recognition of the presumed trigger.
- **Bilateral opacities** consistent with pulmonary edema: **may be detected on CT** or **CXR**.
- **Do NOT need to exclude heart failure**; respiratory failure "*not fully explained by cardiac failure or fluid overload*,".
  - **"objective assessment**"– meaning an **echocardiogram** in most cases — should be performed if there is **no clear risk factor** present like trauma or sepsis.

(Ranieri et al., 2012)

ARDS – Berlin definition

ARDS Severity	Pa02/Fi02	Mortality
Mild	200-300	27%
Moderate	100-200	32%
Severe	<100	45%

With PEEP/CPAP >
5 cmH20

(Ranieri et al., 2012)

The Berlin Definition of ARDS

Table 3. The Berlin Definition of Acute Respiratory Distress Syndrome

	Acute Respiratory Distress Syndrome
Timing	Within 1 week of a known clinical insult or new or worsening respiratory symptoms
Chest imaging[a]	Bilateral opacities—not fully explained by effusions, lobar/lung collapse, or nodules
Origin of edema	Respiratory failure not fully explained by cardiac failure or fluid overload Need objective assessment (eg, echocardiography) to exclude hydrostatic edema if no risk factor present
Oxygenation[b]	
Mild	200 mm Hg $< Pa_{O_2}/F_{I_{O_2}} \leq$ 300 mm Hg with PEEP or CPAP $\geq$5 cm H_2O[c]
Moderate	100 mm Hg $< Pa_{O_2}/F_{I_{O_2}} \leq$ 200 mm Hg with PEEP $\geq$5 cm H_2O
Severe	$Pa_{O_2}/F_{I_{O_2}} \leq$ 100 mm Hg with PEEP $\geq$5 cm H_2O

Abbreviations: CPAP, continuous positive airway pressure; $F_{I_{O_2}}$, fraction of inspired oxygen; Pa_{O_2}, partial pressure of arterial oxygen; PEEP, positive end-expiratory pressure.

[a] Chest radiograph or computed tomography scan.

[b] If altitude is higher than 1000 m, the correction factor should be calculated as follows: [$Pa_{O_2}/F_{I_{O_2}} \times$ (barometric pressure/760)].

[c] This may be delivered noninvasively in the mild acute respiratory distress syndrome group.

(Ranieri et al., 2012)

HISTORICAL NAMES FOR ARDS:

2. What are some other terms that were formerly used to describe the syndrome now referred to as ARDS?

- "Shock Lung" in WW2
- "White Lung"
- **"Non-cardiogenic pulmonary edema"**
- "Hemorrhagic atelectasis"
- **"Post-Traumatic pulmonary insufficiency"**
- "Wet Lung Syndrome"
- "Heroin pulmonary edema"

- *Considering the pathology of ARDS, all these former names are accurate in their description*

ARDS caused by DIRECT INJURY to A-C Membrane

5. What are some common causes of ARDS due to direct lung injury?

- **ASPIRATION**
  - Gastric contents; esp. with ***pH < 2.5***
  - Near drowning; FRESH water or SALT water
- **INHALATION**
  - 02 toxicity; extended periods of Fi02 >.50
  - Toxic gases; ex. Hydrocarbon particles in **smoke inhalation**
- **INFLAMMATION**
  - trauma, esp. pulmonary contusion
  - infection, esp. viral, PCP

ARDS caused by INDIRECT injury to A-C membrane:

What about common causes of ARDS due to indirect lung injury?

- **SEPSIS**;
  - micro-organisms or ***endotoxins*** circulating in blood damage membrane
- **TRAUMA**;
  - circulating inflammatory cytokines from systemic traumatic injury
- **PANCREATITIS**;
  - enzymes released by infected pancreas circulate to lung and cause A-C membrane damage;
  - esp. Severe form of ARDS
- **FAT EMBOLI**

…more INDIRECT causes of ARDS

- **DISSEMINATED INTRAVASCULAR COAGULOPATHY (DIC);**
  - dysfunction in both clotting and fibrinolytic mechanisms; related to ARDS and vice versa
- **DRUG OD**;
  - esp. Heroin and other narcotics;
  - also aspirin, barbiturates and some diuretics;
  - unknown mechanism
- **CNS** disorders;
  - increased ICP and seizures;
  - ***"neurogenic pulmonary edema";***
  - suspected to be from excessive sympathetic outflow causing increased pulmonary pressures to damage A-C

EPIDEMIOLOGY

7. What is the mortality rate of patients with ARDS? Has it improved significantly over the last few decades?

   How has the cause of mortality changed for ARDS patients over the years?

- Incidence difficult to determine due to variety of causes
- ~200,000 cases each year (US); with ~75,000 annual deaths from ARDS (Fan et al., 2018)
  - Globally 3 million cases per year
  - 10% of all ICU admissions
  - 24% of patients on mechanical ventilation
- Mortality remains **35-46%** despite research and improvements in management (Fan et al., 2018)

Features

- **Hypoxemia**
- **Non-cardiogenic pulmonary edema**
- Widespread capillary damage
- Widespread alveolar collapse
- Surfactant deficiency
- Decreased lung compliance



Etiologies of ARDS

- Pathophysiology is similar despite various diverse etiologies
- Occurs in **ALL AGES** of patients
- **SEPSIS** (systemic infection) and **SIRS** (systemic inflammatory response syndrome) are **most common** etiology
- **TRAUMA**
  - both pulmonary and non-pulmonary
- **SHOCK**
  - most likely due to problems causing the shock, i.e. trauma, sepsis, ++ blood transfusions

RTs may contribute to the development of ARDS as well

What is the medical term for illness caused by health professionals or therapy?

Iatrogenic!

- ***"BIOTRAUMA"*** refers to the systemic inflammation caused by ***ventilator induced lung injury (VILI)***
- **OVERDISTENSION** and **SHEARING** injury causes release of **inflammatory mediators**
- Mediators circulate to systemic circulation possibly contributing to **SIRS**

Long time appreciation of volutrauma and VILI



(Gattionni & Protti,2008)

BAROTRAUMA / VOLUTRAUMA / ATELECTRAUMA

Over-distension of lung tissue

Secondary inflammatory response >

Biotrauma

Ventilator-induced lung injury (VILI)

Increased VT well known to contribute to alveolar ***stress/strain***

Leads to chemical mediator cascade

inflammation

biotrauma

multi-organ failure



(Frank & Matthay, 2003)

FLUID TRANSFER ACROSS THE A-C MEMBRANE:

3. How is the transfer/balance of fluids in the lungs affected by ARDS?

- Depends on **Starling's Law of Fluid Movement**
- Two compartments; capillary and interstitial
- **HYDROSTATIC** vs. **OSMOTIC** pressures
- Normally **20 mls/hr** net transfer to interstitial space; absorbed by **lymphatic vessels**
- Permeability is normally a constant
- Changes in hydrostatic pressure are normally caused by LVF or mitral stenosis; leads to ***CARDIOGENIC pulmonary edema***

Town = Alveolar Space



Normal conditions

Oncotic and hydrostatic forces (Starling Forces) are equal

Cardiogenic Pulmonary Edema

- Normal capillary permeability
  - **barrier is intact**
- Increased hydrostatic pressure
  - **ex. PCWP is Increased (> 12 mmHg)**
  - Due to:
    - **L ventricular failure**
    - **Mitral valve stenosis**
    - **PCWP > 20 mmHg = alveolar edema!**

Hydrostatic Pulmonary Edema = Cardiogenic Pulmonary Edema

Water levels has risen (increased hydrostatic pressure), exceeding the forces that resist alveolar flooding, resulting in town flooding (alveolar flooding)

Non-Cardiogenic Pulmonary Edema (ARDS)

- **Increased capillary permeability**
  - Breakdown of normal barrier that prevents leakage of fluid out of the pulmonary capillaries and into the interstitium
    - **barrier is NOT intact**

- **Normal hydrostatic pressure**
  - **Ex. PCWP is NOT ↑'ed**
  - **at normal levels (5-12 mmHg)**
  - ***or slightly increased, but still < 18 mmHg***

Non-Hydrostatic Pulmonary Edema = Non-Cardiogenic Pulmonary Edema

Crack in the dam, allows for flooding. Muddy water represents the protein and inflammatory cells contained in the fluid.

Which one is Cardiogenic Pulmonary Edema? Non-Cardiogenic?





6. How is gas exchange affected in ARDS? Explain.

ARDS Pathophysiology







PATHOGENESIS of ARDS

1. Damage to **Type I Alveolar cells** or **endothelial capillary cells**
2. Release of **chemical mediators**
   - **tumor necrosis factor (TNF), complement fragments, endotoxins**
3. **Chemotaxis** of **neutrophils, macrophages and** other **inflammatory cells**
4. Further release of mediators;
   - **leukotrienes, free O2 radicals, proteases**
5. Chemical mediators cause **microvascular injury**
6. Increased permeability of A-C membrane
7. At first leads to **interstitial edema** and fluid formation
8. Eventually leads to **alveolar edema**

ALVEOLAR EDEMA with ARDS

- **EXUDATIVE** edema fluid as a result of protein influx into alveoli
- Alveolar fluid includes **inflammatory cells** (neutrophils, macrophages), cell debris, plasma proteins (e.g. *albumin*)
- **SURFACTANT abnormality**;
  - possible dysfunction due to damage to SURF layer by **exudate (protein) fluid**
  - Possible damage to Alveolar Type II cells

Normal vs ARDS A-C Membrane



ARDS Pathophysiology



Stages of ARDS Pathogenesis

- **EXUDATIVE PHASE**: alveolar and endothelial damage, inflammatory cell influx, atelectasis, exudative edema, ***hyaline membrane formation***

  [Disruption of A-C interface]

- **FIBRO-PROLIFERATIVE PHASE**: after 1-2 weeks; influx of fibroblasts; fibrin release; reparative changes; **ALV Type II** proliferate to replace damaged **ALV Type I cells**

- **FIBROTIC PHASE**: resolution of inflammation and development of varying degrees of **pulmonary fibrosis; some permanent changes**



.1 Cross-sectional view of alveoli in acute respiratory distress sy
lar consolidation; *AT,* atelectasis; *HM,* hyaline membrane; *M,* ma

Pathophysiology

- Dysfunction related to pathology of **INTERSTITIAL** and **ALVEOLAR EDEMA**
- **Decreased V/Q**
- **Increased SHUNT**
- **SURFACTANT** alterations;
  - increased surface tension; ***decreased CL***
- **Increased PVR**;
  - due to ***hypoxic vasoconstriction***
  - compression by interstitial edema
- **Decreased FRC**;
  - ***decreased CL***

Pathophysiology

- **Decreased lung volumes**
  - FRC, ERV, RV
- **Atelectasis**
- **Refractory hypoxemia**
- **Decreased DLCO**

Clinical Presentation

- Clinical symptoms/signs usually are present after **4-48 hours** from initial injury
- **FIRST SIGN is DYSPNEA**
  - **Usually SEVERE**
- **REFRACTORY HYPOXEMIA** develops with **decreased PaO2/FiO2**
  - ***hyperventilation stimulated by hypoxemia***
- **INSP CRACKLES**
- **Tachypnea**
  - ***"rapid – shallow"*** **breathing pattern**

CXR

- **CXR** initially is normal;
  - lags symptoms;
  - leads to diffuse bilateral alveolar edema,
  - **“ground glass” appearance**
  - normal heart size



Diagnosis

- Generally made by **clinical** and **radiographic** methods
- **HISTORY** of patient very important!
- ***Is patient at risk for development of ARDS?***
- ***Does patient meet criteria for ARDS?***
- Is pulmonary edema due to **CARDIOGENIC** **or** **NON-CARDIOGENIC** factors?

ARDS MANAGEMENT

Let's review…

- **ARDS:**
  - A restrictive disorder of **↓'ed lung compliance**
  - Reduced compliance due to presence of large quantities of **interstitial and alveolar exudate**
  - **Refractory shunt may be present**
  - **Oxygenation and Ventilation support required**



ARDS Case Study

- A 77-year-old man is undergoing mechanical ventilation after severe sepsis and circulatory shock.
- He has a positive fluid balance, and echocardiography has been performed, showing normal left ventricular function. The PCWP is 11 mmHg.
- The patient is 178 cm tall and weighs 60 kg. He was hypertensive and had poor urine output on arrival to ICU. His arterial blood pressure was been supported with IV fluids and norepinephrine infusion.
- 24 hours after ICU admission, he has a positive fluid balance of 2 Liters..

Currently..

- The patient is sedated and on AC-VC
- Ventilator settings:

VT 500 mls, RR, 20 bpm, FIO2 0.60, PEEP 5 cmH20

CXR: bilateral diffuse alveolar infiltrates

ABG: 7.23/55/74/23/0/87%

Place the patient on the current settings and then switch to lung protective strategy

TREATMENT

- ***No specific treatment for the increase in permeability of the A-C membrane***
- Various **pharmacological** **interventions have been investigated**
- Supportive therapy
- **OXYGENATION** and **VENTILATION**
  - **PEEP: low vs high debate**
- Monitor **hemodynamics;**
  - treat with FLUID and VASOPRESSORS to support cardiac output and O_2 delivery

Most important treatment strategy:

- **TREAT or REVERSE the cause of ARDS**
  - if possible!
- **Sepsis** or **pneumonia**:
  - treat aggressively with appropriate anti-microbials
- Many etiologies can **NOT** be treated or reversed; i.e. trauma, aspiration

Trusted evidence.
Cochrane
Informed decisions. Library Better health. Cochrane Database of Systematic Reviews

[Intervention Review]

Pharmacological agents for adults with acute respiratory distress syndro me

Sharon R Lewis[1], Michael W Pritchard[1], Carmel M Thomas[2], Andrew F Smith[3]

[1]Lancaster Patient Safety Research Unit, Royal Lancaster Infirmary, Lancaster, UK. [2]Department of Research and Innovation, Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK. [3]Department of Anaesthesia, Royal Lancaster Infirmary, Lancaster, UK

(Lewis et al., 2019)

Cochrane Review Conclusion

We found insufficient evidence to determine with certainty whether corticosteroids, surfactants, N-acetylcysteine, statins, or beta-agonists were effective at reducing mortality in people with ARDS, or duration of mechanical ventilation, or increasing ventilator-free days. Three studies awaiting classification may alter the conclusions of this review. As the potential long-term consequences of ARDS are important to survivors, future research should incorporate a longer follow-up to measure the impacts on quality of life.

(Lewis et al., 2019)

Sedation and ARDS

Limiting Sedation for Patients with ARDS – Time to Wake Up

Faraaz Ali Shah, MD, Timothy D. Girard, MD, MSCI, and Sachin Yende, MD, MS

- What is the purpose of sedation when managing ARDS patients?
- Tolerate mechanical ventilation
- Minimize patient discomfort
- Improve patient-ventilator synchrony
- Deep sedation no longer recommended, however may be needed occasionally for advanced therapies in severe ARDS
- What is the benefit of limiting sedation?
- Improve ability to participate in mobilization/rehabilitation

What about Neuromuscular Blockade?

ORIGINAL ARTICLE

Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome

The National Heart, Lung, and Blood Institute PETAL Clinical Trials Network*

https://www.nejm.org/doi/full/10.1056/NEJMoa1901686

Mechanical Ventilation Strategies

8. What are some ventilation strategies that are recommended for ARDS?

- Lung Protective Strategy
- Prone Positioning
- High PEEP
- Lung Recruitment Maneuvers (LRM)
- APRV
- ECMO



(Fan et al., 2018)

Ventilation & Oxygenation Goals

- **VC** or **PC**
  - ***Which do you think would be better?***
- **Vt 4-6 mls/kg**
  - **Only ventilation strategy that improves survival!**
  - **pH > 7.25-7.30**
- **Pplat no greater than 30 cmH_2O**
  - *'Lung protective'* strategy
  - ↓ risk of barotrauma
- **PEEP**
  - High levels of PEEP (>10 cmH20) improve oxygenation but not survival
  - *'Open Lung'* strategy
- **Recruitment maneuvers**
  - ex. 30 PEEP x 30 sec.
  - Improve oxygenation but not survival
- **PaO_2 55-80 mmHg or Sa02 88-95%** (ARDSNet Protocol)

Complications of ARDS

- **Multiple organ dysfunction syndrome (MODS):**
  - non-survivors often die from MODS or sepsis
- **Death**
  - up to 25-40% of the cases
- **Pulmonary fibrosis**
- Oxygen toxicity;
  - ***"CATCH 22"*** as it is also the treatment!!
- **BARO/VOLU/BIOTRAUMA**
  - **Ventilator-induced Lung Injury or *VILI***
  - Also "CATCH 22" as ventilation is part of the management!
- **SUPER-infections: MRSA, VRE**

Lung Protective Strategies

- **Alveolar recruitment** and stabilization are important in improving V/Q matching

- High lung volumes carry the risk of **hyperinflation** leading to **alveolar distention** and **volu/barotrauma**

Lung Protective Strategies

Ideally, ***OPEN*** *the lungs and* ***keep them open*** *while avoiding* ***alveolar over-distension!!***

- Use **low Vt**
  - 6 mls/kg (or lower!)
- **Low Pplat's (<30 cmH20)**
- **Higher PEEP (?)**

Lower VTs = Less VILI = ↑ Survival!

- Lower VTs (<7 mls/kg IBW) have proven to ↑ survival in ARDS
- 33% ↓ mortality
  - ($p < 0.001$)
  - (Armato, 1998) in NEJM
- 9% ↓ mortality
  - ($p < 0.005$)
  - (ARDSnet, 2000) in NEJM
- Cochrane review (2013) ↓'ed 28-day mortality
  - (RR 0.74, 95% CI .61-.88)

(Piraino, 2011)

Lower VTs may be better even *WITHOUT ARDS?*

- Retrospective cohort study; 332 patients ***WITHOUT ARDS*** were assessed
- 24% developed ALI/ARDS within 5 days
- Risk factors for development of ARDS were ↑ VT, transfusion blood products, acidemia and hx of ILD
- Females were more likely to have ↑ VT ($p<0.001$) and ARDS, 29 vs 20% ($p = 0.068$)

(Gagic *et al.*, 2004)

Lower VTs may be better even *WITHOUT ARDS?*

- 6 mls/kg vs 10 mls/kg IBW showed benefits for patients ***WITHOUT ARDS***
- ↓ cytokine (IL-6) release (p=0.001)
- ↓ development of lung injury; 2.6% vs 13.5% (p = 0.01)
- Sedation, vasopressors, PEEP and FiO2 were not significantly Δ across groups

(Determann *et al.,* 2010)

Lung Protective Ventilation Strategy

- ***Open the lung … and keep it open!***
- Avoid de-recruitment
- Ventilate at the best compliance
- Pplateau < 30 cmH20



(Jones, 2008)

Open Lung Concept

- VT < 7 mls/kg IBW
- Best PEEP
  - 2-3 cmH20 above Lower Inflection point on PV loop
- ALVEOLI study determined no survival benefit with higher PEEPs vs lower PEEPs
  - (Brower et al., 2004) *NEJM*
- Lung Recruitment manoeuvres

With LOWER VTs, there is a risk for decruitment and atelectasis … so best PEEP and strategies to re-recuit are important!

Ventilation strategies that apply *Open Lung Concept*

- Higher PEEPs
- APRV
- HFOV
- Lung Recruitment Maneuvers (LRM)

Lower PEEP/higher FiO2

FiO_2	0.3	0.4	0.4	0.5	0.5	0.6	0.7	0.7
PEEP	5	5	8	8	10	10	10	12

FiO_2	0.7	0.8	0.9	0.9	0.9	1.0
PEEP	14	14	14	16	18	18-24

Higher PEEP/lower FiO2

FiO_2	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.5
PEEP	5	8	10	12	14	14	16	16

FiO_2	0.5	0.5-0.8	0.8	0.9	1.0	1.0
PEEP	18	20	22	22	22	24

Recruitment Measures

Open Lung Concept

- Goal: Provide enough PEEP to **recruit alveoli** but not so much that healthier regions are **over-distended**
- Combines
  - **Permissive hypercapnia**
  - **PCV or APRV**
  - **PEEP**
    - set above LIP on PV curve
  - Reduced Vt (<7 ml/kg)



RECRUITMENT MEASURES

- Several methods are used:
  - **CPAP level 35-40 cmH20 for 30 - 40 sec**
    - followed by a slow return to previous PEEP level
    - **’30 x 30’**
  - **Series of sigh breaths**
  - **↑’ing HIGH PEEP with APRV (BiLEVEL)**



Critical Care

Lung Recruitment Maneuver (LRM)

- Typically 30 cmH_20 PEEP x 30 sec., or 40 cmH_20 PEEP and 40 sec.
  - Alternative being incremental / decremental methods
- ↑ oxygenation without a Δ mortality
- Balance benefit with risks



Lung Recruitment Maneuver (LRM)

- Are lung units ***recruitable?***
- May be determined by nature of lung injury
- Direct or ***indirect***
- Prone positioning may be considered a type of LRM



(Pelosi, 2010)

Recruitment Maneuvers

- Limited evidence to show advantage over conventional ventilation
- **↑ in oxygenation is generally short term**
  - NOT recommended for routine use
- C-V side effects may be evident
  - **↓ in C.O. and BP (20-30% pts)**

(Kacmerek et al., 2007)

High Frequency Oscillation Ventilation (HFOV)

- HFOV used often for neonatal RDS
- Lung protective strategy (small VTs, high mean airway pressure)
- The Oscillation in ARDS (**OSCAR**) trial, no significant difference in 30-day mortality (primary outcome)
- Osculation for ARDS Treated Early (**OSCILLATE**) trial (5 countries, > 30 ICUs) evaluated use of HFOV for **adult ARDS**
- Study terminated early due to significant ↑ mortality rate among study group vs standard care (47% vs 35%, p = .005)



Airway Pressure Release Ventilation (APRV)

- Also sometimes called: *BiLEVEL, BiVENT*
- ***High PEEP*** for extended time with ***SPON breathing***
  - ***i.e. CPAP with release***
- Inverse ratios of > 4:1
- Short (<1 sec.) release times for EXH of CO2
- Results in sustained recruitment and high Paw
- Evidence generally shows ***↑ oxygenation*** with no significant effect on mortality



FIGURE 2

REPRINTED FROM FRAWLEY PM, HABASHI NM. AIRWAY PRESSURE RELEASE VENTILATION: THEORY AND PRACTICE. AACN CLINICAL ISSUES 2001; 12:234–246, WITH PERMISSION FROM WOLTERS KLUWER HEALTH/LIPPINCOTT, WILLIAMS & WILKINS.

Live lung scanning by the beside

PulmoVista 500 – by Draeger

https://www.youtube.com/watch?v=Twk3bDRJDYM

Prone Positioning

- Adjunctive strategy that has been used to improve oxygenation in patients with severe ARDS.
- Data supports the physiological benefits of prone position
- High-risk intervention

But do the benefits outweigh the risk?

What is Prone Positioning?

- Placing a patient is prone positioning is a strategy that has been used to improve oxygenation and avoid further lung injury in patients with severe ARDS.
- Originally, the physiological benefits did not translate into better patient outcomes.
- Four RCTs in the early 2000s demonstrated that patients who undergone prone positioning experienced an improvement in their oxygenation but none of the trials demonstrated an improved survival.
  - However, these studies did show that prolonged periods of prone ventilation were demonstrated to be both feasible and safe.

Physiology

- Oxygenation improved by:
  - Alveolar recruitment
  - Redistribution of ventilation toward the dorsal regions resulting in enhanced ventilation and perfusion matching
  - Decreased shunt as a result of better perfusion of the previously atelectatic lung regions that are now recruited
  - Elimination of compression of the lungs by the heart

Heart Positioning Changed

- **Cardiomegaly** decreases left mid and lower zone ventilation because of the heart compressing the lung
- Prone allows the heart to lay on the sternum and the mechanical effect on the LLL is relieved

Supine



Prone



(Fessler & Talmor, 2010)

Physiological benefits of prone positioning

Physiology

- ↑'s FRC
- ↑'s C.O.
- ↑'s diaphragmatic excursion
- **↑'s V/Q matching** and gas exchange
  - due to increased surface area of dependent zones
- ↓'s transalveolar stretching forces
- ↓'s PVR
  - probably related to **↓'ed hypoxic pulmonary vasoconstriction** as a result of recruitment of areas with atelectasis



Supine Prone

(Raoof *et al.*, 2010)

Clinical Protocol

- Does not require a special bed
- Requires special care & supportive staff
  - ***Attending physician, RRTs, RNs***
- Support for shoulders, upper chest, pelvis, special pillow
- **Extreme care of ETT & lines – RRTs role!**
- Rotated in 2 step procedure
  - Side then prone
- Pressure care
  - esp. eyes

Complications

- Adequate staff numbers
- Pressure care
- **ETT & Line displacement**
- Obese patient
- Presence of other injuries
- **Need for ↑ sedation**
- Facial edema

PROSEVA Study – the game changer!

- Multi-center RCT
- Inclusion Criteria:
  - Ventilated for < 36 hours
  - Dx w. severe ARDS
    - (defined as P/F ratio < 150 mmHg, FiO2 > .60, PEEP > 5 cmH2O, VTs 6 ml/kg)
- Outcome measured: proportion of patients who died from any cause within 28 days
- Method: Patients were proned for 16 consecutive hours

*(p<0.001)

- No complications existed difference between the two groups

	Prone Group	Supine Group
(n)	237	229
28 day mortality	16%*	32.8%*
90 day mortality	23.6*	41%*

ECMO

- Removes blood from the patient and circulates it through an artificial lung with a pump.
- A method of providing respiration: **CO2 removal** and **O2 uptake.**
- Removes blood from the body →Passes it through a membrane for gas exchange → Returns blood to the body
- membrane lung is a hollow fiber silicone **oxygenator** highly permeable to **CO2** and **O2** gas exchange

Basic operation: Venous – Venous ECMO

- Facilitates gas exchange: blood is removed from the venous side and then pumped back into it
- Does not provide hemodynamic support



ECMO

Advantage

- complete control of patient's cardiac output and gas exchange

Disadvantage

- ligation of a major artery is required and there is the possibility of air or clots in CNS

ECMO Equipment – RT relevance

- Oxygenation
  - FiO2 set on a blender
- SWEEP
  - Measured in L/min
  - Equivalent to Minute Ventilation
  - Set on flowmeter



RT Role in ECMO

ECMO

- Initial FiO2 and Sweep will be set by perfusion
- Blood gases analysis will dictate changes in both
- If PaO2 is decreased, Increase FiO2
- If CO2 needs to be corrected, adjust sweep

Mechanical Ventilation

- Goal is to ventilate using Lung Protection Strategy (i.e. Low volumes, low minute ventilation, high PEEP, low FiO2)
- As pt. improves ECMO decreases work (weans) and ventilator gains it